Online inquiry

IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12051MR)

This product GTTS-WQ12051MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NRP1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001024628.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8829
UniProt ID O14786
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12051MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14976MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ15028MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ6284MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ8679MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ2023MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ8493MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ330MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ8582MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW